AbCellera Biologics Q3 EPS $(0.10) Beats $(0.13) Estimate, Sales $6.60M Miss $11.90M Estimate
Portfolio Pulse from totan@benzinga.com
AbCellera Biologics reported Q3 losses of $(0.10) per share, beating the analyst consensus estimate of $(0.13) by 23.08%. However, the company's quarterly sales of $6.60 million missed the analyst consensus estimate of $11.90 million by 44.55%. This represents a 93.49% decrease over sales from the same period last year.
November 02, 2023 | 8:25 pm
News sentiment analysis
Sort by:
Ascending
NEUTRAL IMPACT
AbCellera Biologics' Q3 earnings per share beat estimates, but sales fell short. This could lead to mixed reactions in the market.
While AbCellera Biologics beat earnings per share estimates, which is generally positive for the stock, it missed on sales estimates, which is generally negative. The mixed results could lead to uncertainty and volatility in the stock's price in the short term.
CONFIDENCE 90
IMPORTANCE 80
RELEVANCE 100